Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olomorasib pharmacokinetics and food effect study in healthy Japanese participants
NCT07124013Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olomorasib (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Olomorasib and Area Under the Concentration versus Time Curve from Time Zero to Time t. Started Sep 2025; status: completed.
02
Drugs
olomorasib
Beyond the preview
Go deeper on NCT07124013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07124013.